Liu M, Bu Y, Chen C, Xu J, Li D, Leng Y, Freeman RB, Meyer ET, Yoon W, Sung M, Jeong M, Lee J, Kang J, Min C, Song M, Zhai Y, Ding Y. Pandemics are catalysts of scientific novelty: Evidence from
COVID
‐19.
J Assoc Inf Sci Technol 2021;
73:1065-1078. [PMID:
35441082 PMCID:
PMC9011856 DOI:
10.1002/asi.24612]
[Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 11/07/2021] [Accepted: 12/08/2021] [Indexed: 11/24/2022]
Abstract
Scientific novelty drives the efforts to invent new vaccines and solutions during the pandemic. First‐time collaboration and international collaboration are two pivotal channels to expand teams' search activities for a broader scope of resources required to address the global challenge, which might facilitate the generation of novel ideas. Our analysis of 98,981 coronavirus papers suggests that scientific novelty measured by the BioBERT model that is pretrained on 29 million PubMed articles, and first‐time collaboration increased after the outbreak of COVID‐19, and international collaboration witnessed a sudden decrease. During COVID‐19, papers with more first‐time collaboration were found to be more novel and international collaboration did not hamper novelty as it had done in the normal periods. The findings suggest the necessity of reaching out for distant resources and the importance of maintaining a collaborative scientific community beyond nationalism during a pandemic.
Collapse